Fisher & Paykel Healthcare Corporation Limited today provided revenue guidance for the financial year ending 31 March 2023, with expectations of operating revenue to be within the range of approximately $1.55 billion to $1.60 billion.
Managing Director Lewis Gradon acknowledged the efforts of the company's customers, clinical partners, suppliers and teams for their response to recent demand surges in both China and North America.
Exchange rates used are NZD:USD 0.63 and NZD:EUR 0.59, compared to exchange rates of NZD:USD 0.58 and NZD:EUR 0.58 as referred to at the time of the November 2022 half year result.
See more
